Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH)’s stock price has dropped by -9.30 in relation to previous closing price of 0.97. Nevertheless, the company has seen a loss of -14.56% in its stock price over the last five trading days. globenewswire.com reported 2025-06-02 that – Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects – – Virtual investor webcast today at 8:00 a.m. EDT – CUPERTINO, Calif.
Is It Worth Investing in Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) Right Now?
Company’s 36-month beta value is 0.11.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RVPH is 41.78M, and currently, short sellers hold a 7.28% ratio of that floaft. The average trading volume of RVPH on June 03, 2025 was 685.99K shares.
RVPH’s Market Performance
RVPH’s stock has seen a -14.56% decrease for the week, with a 0.85% rise in the past month and a -31.25% fall in the past quarter. The volatility ratio for the week is 13.78%, and the volatility levels for the past 30 days are at 8.40% for Reviva Pharmaceuticals Holdings Inc The simple moving average for the past 20 days is -2.68% for RVPH’s stock, with a -31.21% simple moving average for the past 200 days.
Analysts’ Opinion of RVPH
Many brokerage firms have already submitted their reports for RVPH stocks, with ROTH MKM repeating the rating for RVPH by listing it as a “Buy.” The predicted price for RVPH in the upcoming period, according to ROTH MKM is $12 based on the research report published on September 20, 2023 of the previous year 2023.
The Benchmark Company, on the other hand, stated in their research note that they expect to see RVPH reach a price target of $17. The rating they have provided for RVPH stocks is “Speculative Buy” according to the report published on June 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to RVPH, setting the target price at $10 in the report published on January 24th of the previous year.
RVPH Trading at 4.19% from the 50-Day Moving Average
After a stumble in the market that brought RVPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.44% of loss for the given period.
Stock Fundamentals for RVPH
The total capital return value is set at -34.16. Equity return is now at value -916.17, with -281.12 for asset returns.
Based on Reviva Pharmaceuticals Holdings Inc (RVPH), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -73.22. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -1665.07.
Currently, EBITDA for the company is -29.88 million with net debt to EBITDA at 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.54.
Conclusion
In a nutshell, Reviva Pharmaceuticals Holdings Inc (RVPH) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
